Literature DB >> 8863816

Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.

D L Gustafson1, H D Beall, E M Bolton, D Ross, C A Waldren.   

Abstract

Previous studies have indicated that NAD(P)H: quinone oxidoreductase [DT-diaphorase (NQO1)] plays an important role in the bioreductive activation of quinone-containing antitumor agents. Although these studies demonstrated that purified NQO1 can reduce these compounds in vitro, the importance of NQO1 in the intracellular activation of quinone-containing antitumor agents remains controversial. In our study, we transfected human NQO1 into Chinese hamster ovary cells that do not normally express NQO1 activity and obtained stable clones that expressed NQO1 activity of 19-3527 nmol of 2,6-dichlorophenolindophenol reduced/min/mg of protein. The level of NQO1 expression correlated with an increased killing by streptonigrin, EO9 (3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propen ol), and 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone, but mitomycin C sensitivity was independent of this activity. NQO1 expression also led to a slight decrease in the sensitivity of cells to menadione. Our data demonstrate that compounds that are efficient substrates for NQO1 in vitro are also bioactivated in cultured mammalian cells when they are transfected with human NQO1. These results are consistent with the relative abilities of mitomycin C, streptonigrin, EO9, and 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone to serve as substrates for bioreduction by human NQO1, and show that NQO1 levels are not necessarily predictive in terms of sensitivity to mitomycin C.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1996        PMID: 8863816      PMCID: PMC3883621     

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

Review 1.  DT-diaphorase and cancer chemotherapy.

Authors:  R J Riley; P Workman
Journal:  Biochem Pharmacol       Date:  1992-04-15       Impact factor: 5.858

Review 2.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.

Authors:  S R Keyes; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

4.  The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O).

Authors:  F Stirpe; E Della Corte
Journal:  J Biol Chem       Date:  1969-07-25       Impact factor: 5.157

5.  Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.

Authors:  S R Keyes; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

6.  Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.

Authors:  H D Beall; R T Mulcahy; D Siegel; R D Traver; N W Gibson; D Ross
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

7.  Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.

Authors:  A M Malkinson; D Siegel; G L Forrest; A F Gazdar; H K Oie; D C Chan; P A Bunn; M Mabry; D J Dykes; S D Harrison
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

8.  Bioreductive activation of mitomycin C by DT-diaphorase.

Authors:  D Siegel; H Beall; C Senekowitsch; M Kasai; H Arai; N W Gibson; D Ross
Journal:  Biochemistry       Date:  1992-09-01       Impact factor: 3.162

9.  Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.

Authors:  G Powis; P Y Gasdaska; A Gallegos; K Sherrill; D Goodman
Journal:  Anticancer Res       Date:  1995 Jul-Aug       Impact factor: 2.480

10.  Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase.

Authors:  S S Pan; P A Andrews; C J Glover; N R Bachur
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

View more
  4 in total

1.  A system for mutation measurement in mammalian cells: application to gamma-irradiation.

Authors:  T T Puck; R Johnson; S Rasumussen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Characterization of the threshold for NAD(P)H:quinone oxidoreductase activity in intact sulforaphane-treated pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Gary S Krenz; Adam J Gastonguay; Carol L Williams; Brian J Lindemer; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

3.  Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.

Authors:  Hsiu-Ni Kung; Tsai-Yun Weng; Yu-Lin Liu; Kuo-Shyan Lu; Yat-Pang Chau
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.752

Review 4.  Implications of NQO1 in cancer therapy.

Authors:  Eun-Taex Oh; Heon Joo Park
Journal:  BMB Rep       Date:  2015-11       Impact factor: 4.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.